Dayvigo Compounded vs. Branded: What Patients and Prescribers Need to Know

What Is Lemborexant and How Does It Work?

Lemborexant is a dual orexin receptor antagonist that selectively blocks the orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the hypothalamus, reducing the wake-promoting signal that keeps patients awake. Unlike benzodiazepines or Z-drugs, it does not broadly suppress central nervous system activity. The result is a more physiologic transition into sleep.

Mechanism vs. Older Sleep Agents

Older sedative-hypnotics such as zolpidem and temazepam act on GABA-A receptors. That broad receptor activity produces sedation but also generates next-morning cognitive and psychomotor impairment, rebound insomnia on discontinuation, and physical dependence. Lemborexant's orexin-specific targeting leaves GABA-A receptors untouched, which is why SUNRISE-1 showed measurably better next-morning driving performance compared with zolpidem extended-release 6.25 mg at day 1 and day 29 of treatment (1).

Pharmacokinetics at a Glance

Lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours under fasted conditions. Its half-life is roughly 17 to 19 hours, which supports once-nightly dosing but also means accumulation is possible with consecutive high-dose use. The drug is primarily metabolized by CYP3A4, so concomitant CYP3A inhibitors (e.g., fluconazole, clarithromycin) can raise plasma levels significantly. A high-fat meal delays Tmax by about 2 hours, so patients should take it on an empty stomach or after a light meal only (2).

FDA Approval: The Clinical Evidence Base for Branded Dayvigo

Eisai submitted two key phase 3 trials, SUNRISE-1 and SUNRISE-2, to support the December 2019 NDA approval. Both trials used polysomnography (PSG) and subjective patient-reported outcomes to measure sleep onset latency (sLSOL), wake after sleep onset (WASO), and subjective total sleep time (sTST).

SUNRISE-1 Design and Findings

SUNRISE-1 enrolled 291 adults aged 18 to 88 with chronic insomnia disorder and randomized them to lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg, or placebo for 30 nights (1). The co-primary endpoints were subjective sleep onset latency (sSOL) and PSG-measured sleep efficiency on nights 1/2 and 29/30.

Key results from SUNRISE-1:

• Lemborexant 10 mg reduced mean sSOL by 18.7 minutes vs. 6.2 minutes for placebo at day 1/2 (P<0.001).
• PSG sleep efficiency on nights 29/30 was significantly higher for both lemborexant doses compared with placebo.
• Next-morning driving performance, measured by standard deviation of lateral position (SDLP), was significantly better with both lemborexant doses compared with zolpidem ER 6.25 mg at day 1 and day 29 (P<0.05) (1).

That driving-impairment advantage is clinically meaningful for shift workers, older adults, and anyone who needs reliable morning function.

SUNRISE-2: Long-Term Efficacy at 12 Months

SUNRISE-2 (N=949) extended the observation window to 12 months across patients in Japan, the United States, and several other countries. Published in Sleep Medicine, the trial confirmed sustained improvements in sSOL, WASO, and sTST without evidence of tolerance accumulation over time. Lemborexant 5 mg and 10 mg both outperformed placebo on patient-reported outcomes through 12 months of nightly use (3).

Taken together, the two SUNRISE trials represent a dataset of more than 1,200 patients with strong PSG endpoints. That evidence base is what the FDA weighed in granting Schedule IV controlled substance status rather than a more restrictive schedule.

Compounded Lemborexant: What the Market Actually Looks Like

Compounding pharmacies in the United States can legally prepare customized drug formulations under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The rules are specific: a 503A pharmacy may compound a drug for an individual patient with a valid prescription if that drug is not on the FDA's "Demonstrably Difficult to Compound" list, among other conditions. A 503B outsourcing facility may bulk compound drugs that appear on the FDA's drug shortage list.

Is Lemborexant on the FDA Shortage List?

No. As of mid-2025, lemborexant (Dayvigo) does not appear on the FDA drug shortage database (4). Without shortage designation, 503B outsourcing facilities have no statutory basis for bulk compounding lemborexant. Some 503A pharmacies may still compound it for individual patients under narrow circumstances, but doing so for broad commercial dispensing would fall outside federal guidelines.

What Compounded Lemborexant Typically Looks Like

Compounded lemborexant, where it is encountered, typically appears as:

• Oral capsules at doses matching the branded product (5 mg, 10 mg) or custom strengths
• Sublingual troches at 2.5 mg to 10 mg, sometimes marketed for "faster onset"
• Combination formulations pairing lemborexant with melatonin or L-theanine

None of these preparations have undergone FDA review for bioequivalence, dissolution rate, or stability. The sublingual troche format, in particular, involves a different route of administration than the FDA-approved oral tablet, which could alter pharmacokinetics in ways that are not characterized by any published data.

No Bioequivalence Data Exists for Compounded Versions

This is the central clinical problem. The FDA approval of Dayvigo is tied to the specific tablet formulation tested in SUNRISE-1 and SUNRISE-2. A compounded capsule using raw lemborexant API from an unverified supplier may have different dissolution kinetics, particle size distribution, and excipient interactions. There are no published pharmacokinetic studies comparing compounded lemborexant to branded Dayvigo. Prescribing clinicians who recommend a compounded version are therefore operating without bioequivalence evidence. The American Society of Health-System Pharmacists (ASHP) guidelines on compounding state clearly that compounded preparations are not FDA-approved and lack the manufacturing controls of commercial drug products (5).

Regulatory and Legal Risk for Prescribers and Pharmacies

The DEA classifies lemborexant as Schedule IV. Controlled substance compounding carries additional scrutiny beyond non-scheduled drugs. Under the Controlled Substances Act, compounding a Schedule IV substance without proper DEA registration and without meeting the legal compounding thresholds exposes both the pharmacy and the prescriber to federal liability.

FDA Enforcement Posture on Unapproved Compounded Drugs

The FDA has increasingly targeted compounding pharmacies that produce commercially available drugs without shortage justification. Between 2020 and 2024, the agency issued multiple warning letters to 503A and 503B pharmacies for compounding drugs that were both commercially available and not on shortage lists. The specific legal basis is that compounding a drug that is "essentially a copy" of an approved product, without shortage or patient-specific necessity, violates the FDCA (6).

Prescribers who write prescriptions explicitly directing dispensing from a compounding pharmacy for a non-shortage drug may face scrutiny from their state medical boards, particularly if there is no documented clinical rationale in the patient chart.

What "Patient-Specific Need" Means in Practice

The one defensible scenario for compounded lemborexant is a patient with a genuine allergy to an excipient in the branded tablet. Dayvigo tablets contain microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, silicon dioxide, and magnesium stearate. A documented allergy to magnesium stearate, for example, could theoretically support a 503A compounding prescription. That should be documented clearly in the patient record.

Clinical Decision Framework: Branded vs. Compounded Lemborexant

The table below summarizes the key comparison points a prescriber should weigh.

| Factor | Branded Dayvigo | Compounded Lemborexant | |---|---|---| | FDA approval | Yes (Dec 2019) | No | | Bioequivalence data | Yes (NDA studies) | None published | | DEA Schedule IV compliance | Confirmed | Variable by pharmacy | | Manufacturing quality (cGMP) | Yes | 503A: not required; 503B: required but shortage rule not met | | Available doses | 5 mg, 10 mg tablets | Custom (variable) | | Insurance coverage | Possible with PA | No coverage | | Cost without insurance | ~$400-$500/month | ~$60-$150/month | | Clinical trial evidence | SUNRISE-1 and SUNRISE-2 | None | | Next-morning impairment studied | Yes (SUNRISE-1 SDLP data) | No |

Cost is often the argument made for compounded versions. At $60 to $150 per month compared with $400 to $500 for branded Dayvigo, the gap is significant for uninsured patients. That gap, however, does not resolve the bioequivalence question or the regulatory exposure.

Dosing, Titration, and Special Populations for Branded Dayvigo

The FDA-approved starting dose is 5 mg taken immediately before bed, with no more than 7 to 8 hours remaining before planned waking. Dose may be increased to 10 mg if 5 mg is tolerated but insufficient. The 10 mg dose should not be used in patients taking moderate CYP3A4 inhibitors.

Older Adults (Age 65 and Above)

Lemborexant was specifically studied in older adults in SUNRISE-1, which included participants up to age 88. The FDA label does not require dose reduction in patients over 65, but clinicians should start at 5 mg and assess next-morning function carefully. The 2023 American Geriatrics Society Beers Criteria noted that orexin receptor antagonists, as a class, carry a lower fall and cognitive risk profile than benzodiazepines and Z-drugs in older adults (7).

Hepatic Impairment

Mild hepatic impairment (Child-Pugh A): no dose adjustment needed. Moderate hepatic impairment (Child-Pugh B): maximum dose is 5 mg. Severe hepatic impairment (Child-Pugh C): lemborexant is not recommended. The prescribing information provides explicit guidance here because CYP3A4 hepatic metabolism determines drug clearance (2).

Patients With Narcolepsy or Cataplexy

Lemborexant is contraindicated in patients with narcolepsy. Blocking orexin signaling in a patient whose orexin system is already depleted (as in Type 1 narcolepsy) could worsen cataplexy and sleep fragmentation. This contraindication applies to any formulation, branded or compounded.

Dayvigo in Context: Where It Fits Against Other Approved Insomnia Drugs

The DORA class now includes two approved agents in the United States: suvorexant (Belsomra, approved 2014) and lemborexant (Dayvigo, approved 2019). A 2022 network meta-analysis published in The Lancet examined 30 trials covering 16 drugs for chronic insomnia. Lemborexant ranked among the best-tolerated agents for subjective total sleep time improvement and had a favorable next-day functioning profile relative to most benzodiazepines (8).

Comparison with Suvorexant

Suvorexant is approved at 10 mg and 20 mg. It also carries a Schedule IV designation. Head-to-head data between the two agents is limited, but pharmacokinetic differences are notable: suvorexant has a longer half-life (12 hours at the approved dose vs. 17-19 hours for lemborexant at 10 mg, though inter-individual variability matters). The SUNRISE-1 driving data gave lemborexant a measurable advantage over zolpidem, but no trial has directly compared next-morning impairment between the two DORAs using standardized driving simulation.

Comparison with Cognitive Behavioral Therapy for Insomnia (CBT-I)

The American College of Physicians (ACP) 2016 guideline and subsequent updates recommend CBT-I as first-line treatment for chronic insomnia disorder over any pharmacologic agent (9). Lemborexant is appropriate for patients who have not responded to or do not have access to CBT-I, or as a bridge therapy during CBT-I initiation. Prescribers should document that CBT-I was considered or offered.

As the 2016 ACP Clinical Practice Guideline states: "We recommend that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder." Pharmacologic options including DORAs are positioned as second-line or adjunctive after this threshold.

Safety Profile: What the Trial Data and Post-Market Surveillance Show

Lemborexant's most common adverse effects in SUNRISE-1 and SUNRISE-2 were somnolence (reported by approximately 10% of patients on 10 mg vs. 1% placebo) and headache (approximately 6% on 10 mg) (1). The incidence of sleep paralysis and hypnagogic hallucinations was low but non-zero, consistent with the class effect of orexin blockade.

Abuse and Dependence Potential

Schedule IV classification reflects a recognized but limited potential for dependence. In a 12-month study, no evidence of rebound insomnia or withdrawal syndrome was observed after abrupt discontinuation in the SUNRISE-2 long-term cohort (3). That is a meaningful difference from the Z-drugs, which carry well-documented rebound insomnia on cessation. Compounded formulations with altered release profiles could theoretically change this risk profile, though no data exist to quantify that change.

Complex Sleep Behaviors

The FDA added a boxed warning in 2019 to the entire class of sedative-hypnotics, including DORAs, for complex sleep behaviors (sleepwalking, sleep driving, preparing and eating food while asleep). This risk is present with branded Dayvigo and would presumably carry over to any compounded equivalent delivering the same active moiety. Patients with a personal or family history of sleepwalking should be counseled carefully before starting any sedative-hypnotic (6).

Insurance Coverage and Prior Authorization for Dayvigo

Most commercial insurance plans place Dayvigo on Tier 3 or Tier 4, often with a prior authorization (PA) requirement. A typical PA form asks for:

1. Documentation of chronic insomnia disorder lasting at least 3 months
2. Failure or contraindication to a Tier 1 or Tier 2 generic agent (e.g., doxepin 3-6 mg, zolpidem 5-10 mg)
3. Clinical rationale for choosing a DORA over a Z-drug

Medicare Part D coverage varies by plan. Patients on fixed incomes who cannot afford branded Dayvigo should be directed to the Eisai patient assistance program, which provides free drug to qualifying patients, rather than defaulting to a compounded version without verified quality.

Prescriber Checklist Before Writing for Lemborexant

Use this checklist before issuing a prescription for any lemborexant formulation.

• Confirmed diagnosis of chronic insomnia disorder (duration >3 months, frequency >3 nights/week)
• CBT-I offered or documented as inaccessible
• CYP3A4 drug interaction screen completed
• Hepatic function assessed; Child-Pugh class documented
• Narcolepsy or cataplexy ruled out
• Complex sleep behavior history obtained
• Pregnancy and breastfeeding status confirmed
• Driving or operating machinery counseling documented
• If branded: PA initiated or GoodRx/patient assistance discussed
• If compounded: documented excipient allergy in chart; 503A pharmacy verified; legal exposure acknowledged

A prescribing clinician who ticks every box on this list and still chooses a compounded formulation for a patient with a genuine excipient allergy is acting within defensible clinical and legal boundaries. A clinician who bypasses this checklist and routes patients to a compounding pharmacy primarily on cost grounds is not.